Ftse Mib
33.736,40
-0,03%
DAX
17.896,50
-0,14%
S&P 500
5.064,20
0,91%
NASDAQ
15.840,96
1,51%
Bitcoin
59.179,96
1,62%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Lexicon Pharmaceuticals Inc (LXRX) Lexicon Pharmaceuticals Inc (LXRX) Notizie

Lexicon Pharmaceuticals Inc

LXRX
1,66
0,01 (0,61%)
Dopo l'orario di negoziazione
Ultimo aggiornamento: 01:17:50
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
02/5/202422:05GLOBELexicon Pharmaceuticals Reports First Quarter 2024 Financial..
29/4/202415:00GLOBELonnel Coats Retires as Chief Executive Officer and Board..
29/4/202413:00GLOBELexicon Pharmaceuticals to Host First Quarter 2024 Financial..
18/4/202414:00GLOBELexicon Pharmaceuticals to Host 2024 Investor Day
03/4/202414:00GLOBELexicon Pharmaceuticals to Participate in the 23rd Annual..
25/3/202414:20GLOBEClinical Data on the Impact of Sotagliflozin on Stroke and..
12/3/202413:00GLOBENew Post Hoc Analysis of inTandem3 Study Demonstrates..
11/3/202421:25EDGAR2Form PRE 14A - Other preliminary proxy statements
11/3/202412:26EDGAR2Form 8-K - Current report
11/3/202412:15GLOBELexicon Pharmaceuticals Reports Fourth Quarter..
11/3/202412:05GLOBELexicon Announces Oversubscribed $250 Million Private..
11/3/202412:00GLOBELexicon Preparing to Resubmit Sotagliflozin NDA for Type 1..
29/2/202422:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202422:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202422:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202422:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202422:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202422:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202422:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202422:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202422:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202422:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202413:00GLOBELexicon Pharmaceuticals Provides Business and Pipeline..
29/12/202323:29EDGAR2Form 8-K - Current report
29/12/202323:27EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
29/12/202322:04EDGAR2Form 8-K - Current report
21/12/202322:15GLOBELexicon Pharmaceuticals To Participate In The 42nd Annual..
30/11/202313:30GLOBELexicon Enrolls First Patient in Phase 2b Progress Study of..
22/11/202313:30GLOBELexicon Pharmaceuticals to Participate in the 35th Annual..
17/11/202322:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/11/202323:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/11/202320:10GLOBEINPEFA® (sotagliflozin) Use Associated With Early Clinical..
10/11/202322:01GLOBELexicon Pharmaceuticals to Participate in the Jefferies..
08/11/202322:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202313:22EDGAR2Form 8-K - Current report
08/11/202313:00GLOBELexicon Pharmaceuticals Reports Third Quarter 2023 Financial..
03/11/202314:00GLOBELexicon Pharmaceuticals to Host Third Quarter 2023 Financial..
02/11/202314:00GLOBEData on Early Clinical Benefit for INPEFA® (Sotagliflozin)..
01/11/202314:00GLOBEINPEFA® (Sotagliflozin) Receives Coverage From Express..
31/10/202321:01GLOBELexicon Strengthens Management Team With Two New Executives
30/10/202321:01GLOBENew Data Relating to Sotagliflozin to be Presented at the..
17/10/202322:01GLOBEData From Two Studies Demonstrating Positive Financial..
11/10/202322:06EDGAR2Form 8-K - Current report
11/10/202322:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/10/202322:01EDGAR2Form 3 - Initial statement of beneficial ownership of..
11/10/202315:00GLOBEData Demonstrating Financial Impact of INPEFA®..
09/10/202322:01GLOBEINPEFA® (Sotagliflozin) Receives Preferred Formulary Status..
09/10/202314:00GLOBETom Garner Joins Lexicon as Senior Vice President and Chief..
28/9/202315:00GLOBELexicon to Present Post Hoc Analysis of Scored Clinical..
Apertura: 1,73 Min: 1,65 Max: 1,75
Chiusura: 1,65

La tua Cronologia

NASDAQ
LXRX
Lexicon Pharmaceuticals
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network